ExpreS2ion Biotech

"Over the last two years, Dr. Ranthe and Dr. Thorn have played key roles in the development of ES2B-C001," comments Bent Frandsen, Chief Executive Officer. "I extend my gratitude to them for their contributions to the Company, our investors, and the individuals whose well-being we aspire to enhance."

"I am proud to have been a member of the leadership team that readied ExpreS²ion for clinical development and formed world-class scientific advisory boards. With the clinical development plan for the ES2B-C001 therapeutic breast cancer vaccine so mature, it will be exciting to follow the next steps for this promising asset. I sincerely hope ExpreS²ion will be successful in bringing this vaccine to cancer patients." says Dr. Mattis Ranthe, Chief Medical Officer.

"Through the adjustment of our headcount and the pursuit of other strategic pathways for the ES2B-C001 breast cancer vaccine program, the Company extends its financial runway beyond 2024, as previously announced," reiterates Bent Frandsen, Chief Executive Officer. "Our strategic focus remains on optimizing our R&D initiatives and development pipeline by harnessing the capabilities of our Phase III clinically validated ExpreS2^TM platform. This approach enables us to prioritize the development of innovative vaccines with a faster and more cost-efficient path to value generation."

Certified Adviser

Svensk Kapitalmarknadsgranskning AB